Teachers Retirement System of The State of Kentucky Makes New Investment in Amneal Pharmaceuticals, Inc. $AMRX

Teachers Retirement System of The State of Kentucky acquired a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 40,000 shares of the company’s stock, valued at approximately $497,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Kemnay Advisory Services Inc. purchased a new position in Amneal Pharmaceuticals during the fourth quarter worth about $26,000. Federated Hermes Inc. grew its holdings in Amneal Pharmaceuticals by 1,680.6% in the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock valued at $29,000 after buying an additional 2,168 shares during the period. Comerica Bank increased its stake in shares of Amneal Pharmaceuticals by 186.7% during the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after acquiring an additional 1,957 shares during the last quarter. Spire Wealth Management lifted its holdings in shares of Amneal Pharmaceuticals by 66.6% during the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after acquiring an additional 1,023 shares during the period. Finally, Transamerica Financial Advisors LLC boosted its position in shares of Amneal Pharmaceuticals by 541.9% in the fourth quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock worth $37,000 after acquiring an additional 2,460 shares during the last quarter. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on AMRX shares. UBS Group upped their price target on shares of Amneal Pharmaceuticals from $19.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday. Barclays boosted their price objective on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Weiss Ratings downgraded Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, May 26th. Wall Street Zen raised Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. Finally, Zacks Research cut Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Five equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $16.60.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, Director Deborah M. Autor sold 34,819 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $12.94, for a total transaction of $450,557.86. Following the completion of the sale, the director directly owned 93,660 shares of the company’s stock, valued at approximately $1,211,960.40. This represents a 27.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 17.30% of the company’s stock.

Amneal Pharmaceuticals Stock Performance

NASDAQ AMRX opened at $18.04 on Friday. The firm has a market capitalization of $5.76 billion, a price-to-earnings ratio of 47.47 and a beta of 1.26. Amneal Pharmaceuticals, Inc. has a one year low of $7.66 and a one year high of $18.08. The company’s 50 day moving average price is $14.95 and its 200 day moving average price is $13.86.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. The company had revenue of $722.52 million during the quarter. Sell-side analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current fiscal year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.